Clinical Trials
3
Active:0
Completed:1
Trial Phases
1 Phases
Phase 3:3
Drug Approvals
4
NMPA:2
HSA:2
Drug Approvals
Budesonide Enteric Capsules
- Product Name
- 布地奈德肠溶胶囊
- Approval Number
- 国药准字HJ20230130
- Approval Date
- Nov 21, 2023
NMPA
Eravacycline Hydrochloride for Injection
- Product Name
- 依嘉
- Approval Number
- 国药准字HJ20233135
- Approval Date
- Mar 15, 2023
NMPA
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 3
3 (100.0%)Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301
Phase 3
Completed
- Conditions
- Primary Immunoglobulin a Nephropathy (IgAN)
- Interventions
- Drug: Nefecon
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Everest Medicines (Singapore) Pte. Ltd.
- Target Recruit Count
- 21
- Registration Number
- NCT05534919
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
Booster Superiority Study of PTX-COVID19-B Compared to Vaxzevria® in Adults Aged 18 Years and Older
Phase 3
Not yet recruiting
- Conditions
- SARS-CoV-2 Infection
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2022-09-09
- Lead Sponsor
- Everest Medicines (Singapore) Pte. Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT05534035
Booster Study of PTX-COVID19-B in Adults Aged 18 Years and Older
Phase 3
Not yet recruiting
- Conditions
- SARS-CoV-2 Infection
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2022-09-09
- Lead Sponsor
- Everest Medicines (Singapore) Pte. Ltd.
- Target Recruit Count
- 3800
- Registration Number
- NCT05534048
News
No news found